MODERATOR
:
SPEAKER
(S):
Olive Sturtevant, MHP, MT(ASCP)SBB, SLS, CQA(ASQ), Administrative Director of Connell & O'Reilly Families, Dana Farber Cancer Institute
Investigation and Reporting of Adverse Events Related to the Infusion of Cellular Therapy Products,,,,
Karen Snow, (ASCP)BB, CQA(ASQ), Quality Manager, Bone Marrow Transplant Program, Massachusetts General Hospital
Overview of Current Infusion and Reporting Practices
Dr. Michael Linenberger, MD, Medical Director, Apheresis & Cellular Therapy, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
The Care and Handling of Stem Cell Products and Recipients at the Time of Infusion
Description
Adverse events and reactions related to the infusion of cellular therapy products are varied and oftentimes not attributed to the product. This session will discuss what constitutes an adverse event or reaction related to CT product infusion, how events may be categorized and what steps may be taken to avoid them in the future. Current practices and uniformity of handling such events will be examined.
LEARNER OUTCOMES:
-
Assess current infusion practices in cellular therapy (CT) and recognize the relationship between CT products and adverse events.
-
Discuss types of adverse events and reactions related to CT product infusion.
-
Investigate methods for capture of adverse events and adverse event reporting including reporting of adverse events to the Center for International Blood and Marrow Transplant Research.
-
Provide a summary of the range of adverse event reports in the CT community.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.